Evogene reports third quarter 2013 financial results

November 3, 2013 |

In Israel, Evogene announced its financial results for the third quarter and nine months ended September 30, 2013.

Evogene saw a total comprehensive loss of $4.7 million for the first 9 months, compared to a total comprehensive loss of $1.8 million for the same period in 2012. Total comprehensive loss for the third quarter of 2013 was $2.3 million, compared to a total comprehensive loss of $1.0 million for the same period in 2012. Cost of Revenues for the third quarter of 2013 was $2.6 million, compared to $2.4 million for the same period in 2012.

This increase in costs primarily relates to the expansion in the Company’s scope of activities in order to meet the obligations of its various contractual agreements.

More on the story.

Category: Digest Index

Thank you for visting the Digest.